Visual Outcomes Following Bilateral Implantation of Two Diffractive Trifocal Intraocular Lenses in 10 084 Eyes

PURPOSE: To investigate refractive and visual acuity outcomes, patient satisfaction, and spectacle independence at 3 months of 2 diffractive (non-toric) trifocal intraocular lenses (IOLs) in a large series of patients. DESIGN: Multicenter, retrospective, nonrandomized clinical study. METHODS: Patients underwent lens phacoemulsification and were implanted bilaterally with a diffractive trifocal IOL: FineVision Micro F (PhysIOL SA, Liege, Belgium) or AT Lisa tri 839MP (Carl Zeiss AG, Jena, Germany). Surgeries were performed between 2011 and 2015 with at least 3 months of follow-up. Visual and refractive performance, patient satisfaction, and spectacle independence were evaluated. RESULTS: A total of 10 084 trifocal IOLs were bilaterally implanted (5802 FineVision in 2901 patients and 4282 AT Lisa in 2141 patients). Three-month mean ( standard deviation) acuity: AT Lisa, binocular uncorrected distance visual acuity (UDVA), -0.01 logMAR +/- 0.06; monocular distance corrected visual acuity (CDVA), 0.02 logMAR +/- 0.06; binocular uncorrected near visual acuity (UNVA) at 40 cm, 0.05 logMAR +/- 0.08; binocular uncorrected intermediate visual acuity (UIVA) at 80 cm, -0.05 logMAR +/- 0.14; postoperative spherical equivalent, 0.26 D +/- 0.47; cylinder - 0.34 D +/- 0.38; Fine-Vision Micro F, binocular UDVA, 0.01 logMAR 0.05; monocular CDVA, 0.03 logMAR +/- 0.06; binocular UNVA, 0.05 logMAR +/- 0.08; binocular UIVA, -0.05 logMAR +/- 0.12; spherical equivalent, 0.34 D +/- 0.50; cylinder -0.39 D +/- 0.40. The IOLs were equivalent in achieving spectacle independence; 98% were "satisfied" to "very satisfied" with their IOL performance. CONCLUSIONS: In this retrospective study with over 5000 patients, implantation of both trifocal IOL models provided good functional distance, intermediate, and near visual acuity, resulting in high levels of both spectacle independence and patient satisfaction. ((C) 2017 Elsevier Inc. All rights reserved.)